* PROCEPT BioRobotics Corp PRCT.OQ PRCT.O is expected
to show
a rise in quarterly revenue when it reports results on July
27.
* The Redwood City California-based company is expected to
report
a 82.5% increase in revenue to $30.456 million from $16.69
million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for PROCEPT BioRobotics
Corp
is for a loss of 57 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for PROCEPT
BioRobotics Corp is $49, above its last closing price
of $36.10.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.58 -0.58 -0.63 Missed -8.4
Dec. 31 2023 -0.55 -0.54 -0.56 Missed -2.9
Sep. 30 2022 -0.48 -0.48 -0.51 Missed -6
Jun. 30 2022 -0.48 -0.48 -0.43 Beat 10.8
Mar. -0.48 -0.47 -0.39 Beat 17.5
31 2022
Dec. 31 2021 -0.41 -0.39 -0.42 Missed -7.7
Sep. 30 2021 -0.42 -0.42 -1.22 Missed -192.2
This summary was machine generated July 25 at 18:33 GMT. All
figures in US dollars unless otherwise stated